Grünenthal PRO Partners with SHL Medical for Final Assembly Services
Grünenthal PRO, part of the Grünenthal company, is excited to announce a new partnership with SHL Medical, a leader in drug delivery systems. This collaboration is set to enhance the final assembly services for the Molly autoinjectors, marking a significant step in the world of injection-based therapies.
Enhancing Capacity for Autoinjector Assembly
The alliance aims to expand the capability for assembling SHL Medical's autoinjectors. By 2026, Grünenthal PRO plans to install additional state-of-the-art assembly lines at its facility in Origgio, Italy. These lines will specifically cater to the Molly autoinjectors, significantly improving the overall speed to market for pharmaceutical and biotechnology companies.
Significance of High-Speed Assembly Lines
The new assembly lines are expected to play a crucial role in accelerating production timelines. Leveraging Grünenthal's decade-long experience in assembling SHL autoinjectors, these enhancements will provide a more agile response to market demands.
Delivering Quality Through Expertise
With this partnership, SHL Medical's customers will gain access to Grünenthal PRO's well-established expertise in delivering high-quality contract manufacturing services. This collaboration promises not just efficiency but also reliability in producing complex drug delivery systems.
Commentary from Leadership
Victor Barbosa, the Executive Vice President of Global Operations at Grünenthal, underscored the importance of speed-to-market in today’s dynamic biopharma landscape. He highlights how Grünenthal's expertise in the final assembly of autoinjectors, combined with the new high-speed line coming in 2026, positions them as a robust partner for injectable therapies around the globe.
Investing in Future Technologies
The Molly autoinjector platform is designed using cutting-edge technology that helps companies expedite their time to market while minimizing the need for large initial investments. Its success in securing combination product approvals speaks to its potential and adaptability.
Partnership Growth and Development
Markus Puusepp, Chief Growth Officer at SHL Medical, expressed enthusiasm about furthering the partnership with Grünenthal PRO. He noted that the collaboration builds on several years of successful projects. This strategic alliance is a testament to their commitment to delivering innovative drug delivery solutions that meet market needs.
Overview of SHL Medical
SHL Medical stands out as a premier solutions provider in advanced drug delivery, focusing on creating patient-centric autoinjectors, pen injectors, and specialty delivery systems. Their global team, operating across multiple locations, emphasizes sustainability and customization to meet the unique demands of their clientele.
About Grünenthal PRO
Grünenthal PRO, as the contract manufacturing division of Grünenthal, offers a complete range of services. With an emphasis on injectable therapies, the company is dedicated to enhancing the efficiency and quality of pharmaceutical delivery systems.
Frequently Asked Questions
What is the focus of the Grünenthal PRO and SHL Medical partnership?
The partnership focuses on improving the final assembly of Molly autoinjectors to accelerate production and enhance quality in drug delivery solutions.
When will the new assembly lines be operational?
The new assembly lines at Grünenthal PRO's facility in Origgio are expected to be operational in 2026.
What advantages do the Molly autoinjectors provide?
Molly autoinjectors offer a modular platform that aids in reducing investments and speeding up the timeline for market launch.
Who can benefit from this collaboration?
SHL Medical's customers, especially those in pharmaceutical and biotech industries, will gain improved access to reliable manufacturing services through this partnership.
What is Grünenthal PRO's expertise in the industry?
Grünenthal PRO specializes in final assembly, packaging, and labeling for injectable therapies, offering high quality and efficient services to global health firms.
